Rocket Pharmaceuticals offers to sell up to $100M in common stock

On March 10, 2026, Rocket Pharmaceuticals (RCKT) entered into a sales agreement with Cantor Fitzgerald & Co., with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $100,000,000, through the Sales Agent. The Shares to be offered and sold under the Sales Agreement, if any, will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission on March 2, 2026. The Company filed a prospectus supplement with the SEC on March 10, 2026 in connection with the offer and sale of the Shares pursuant to the Sales Agreement.